{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:18:38Z","timestamp":1783703918149,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["41138"],"award-info":[{"award-number":["41138"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s11033-021-06855-3","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T16:29:55Z","timestamp":1634920195000},"page":"171-178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Contribution of HLA class II genes, DRB4*01:01, DRB1*07:01, and DQB1*03:03:2 to clinical features of Vitiligo disease in Iranian population"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-2472","authenticated-orcid":false,"given":"Roya","family":"Ghaffarnia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Saffarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Shahbazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3524-5425","authenticated-orcid":false,"given":"Mahdi","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"1","key":"6855_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41702-017-0012-5","volume":"2","author":"R Rahman","year":"2018","unstructured":"Rahman R, Hasija YJBD (2018) Exploring vitiligo susceptibility and management: a brief review. Biomed Dermatol 2(1):1\u201313","journal-title":"Biomed Dermatol"},{"key":"6855_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1087-0024.2004.00825.x","volume":"9","author":"A Wankowicz-Kalinska","year":"2004","unstructured":"Wankowicz-Kalinska A et al (2004) Autoimmune aspects of depigmentation in vitiligo. J Invest Dermatol Sympos Proc 9:68\u201372","journal-title":"J Invest Dermatol Sympos Proc"},{"key":"6855_CR3","volume-title":"Genetic architecture of vitiligo and vitiligo subtypes, The","author":"GHL Roberts","year":"2019","unstructured":"Roberts GHL (2019) Genetic architecture of vitiligo and vitiligo subtypes, The. University of Colorado at Denver, Anschutz Medical Campus, Aurora"},{"issue":"6","key":"6855_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4103\/ijd.IJD_291_20","volume":"65","author":"SJ Ghosh","year":"2020","unstructured":"Ghosh SJ (2020) Chemical vitiligo: a subset of vitiligo. Indian J Dermatol 65(6):443","journal-title":"Indian J Dermatol"},{"issue":"1","key":"6855_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pcmr.12848","volume":"33","author":"GH Roberts","year":"2020","unstructured":"Roberts GH et al (2020) The genetic architecture of vitiligo. Pigment Cell Melanoma Res 33(1):8\u201315","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"6855_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/gene.2009.83","volume":"11","author":"L Handunnetthi","year":"2010","unstructured":"Handunnetthi L et al (2010) Regulation of major histocompatibility complex class II gene expression, genetic variation and disease. Gene Immun 11(2):99\u2013112","journal-title":"Gene Immun"},{"issue":"5","key":"6855_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1073\/pnas.1523482113","volume":"113","author":"G Cavalli","year":"2016","unstructured":"Cavalli G et al (2016) MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. Proc Natl Acad Sci U S A 113(5):1363\u20131368","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6855_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3892\/etm.2021.9743","volume":"21","author":"SL Said-Fernandez","year":"2021","unstructured":"Said-Fernandez SL et al (2021) Novel immunological and genetic factors associated with vitiligo: a review. Exp Ther Med 21(4):312","journal-title":"Exp Ther Med"},{"issue":"3","key":"6855_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jdermsci.2005.06.004","volume":"39","author":"X-J Zhang","year":"2005","unstructured":"Zhang X-J, Chen J-J, Liu J-B (2005) The genetic concept of vitiligo. J Dermatol Sci 39(3):137\u2013146","journal-title":"J Dermatol Sci"},{"issue":"6","key":"6855_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/jid.2011.12","volume":"131","author":"Y Jin","year":"2011","unstructured":"Jin Y et al (2011) Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol 131(6):1308\u20131312","journal-title":"J Invest Dermatol"},{"issue":"4","key":"6855_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5114\/pdia.2014.43497","volume":"31","author":"R Czajkowski","year":"2014","unstructured":"Czajkowski R, M\u0119ci\u0144ska-Jundzi\u0142\u0142 KJ, Alergologii AP (2014) Current aspects of vitiligo genetics. Postepy Dermatol Alergol 31(4):247","journal-title":"Postepy Dermatol Alergol"},{"issue":"5","key":"6855_CR12","doi-asserted-by":"publisher","first-page":"e0216941","DOI":"10.1371\/journal.pone.0216941","volume":"14","author":"D-H Shin","year":"2019","unstructured":"Shin D-H et al (2019) HLA alleles, especially amino-acid signatures of HLA-DPB1, might contribute to the molecular pathogenesis of early-onset autoimmune thyroid disease. PLoS ONE 14(5):e0216941","journal-title":"PLoS ONE"},{"issue":"1","key":"6855_CR13","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1038\/s41467-020-18204-2","volume":"11","author":"CG Rappazzo","year":"2020","unstructured":"Rappazzo CG, Huisman BD, Birnbaum ME (2020) Repertoire-scale determination of class II MHC peptide binding via yeast display improves antigen prediction. Nat Commun 11(1):4414","journal-title":"Nat Commun"},{"issue":"4","key":"6855_CR14","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.4049\/jimmunol.1000629","volume":"185","author":"DK Cole","year":"2010","unstructured":"Cole DK et al (2010) Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 185(4):2600\u20132610","journal-title":"J Immunol"},{"issue":"1","key":"6855_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/jid.2011.240","volume":"132","author":"A Singh","year":"2012","unstructured":"Singh A et al (2012) HLA alleles and amino-acid signatures of the peptide-binding pockets of HLA molecules in vitiligo. J Invest Dermatol 132(1):124\u2013134","journal-title":"J Invest Dermatol"},{"issue":"5","key":"6855_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2230.2009.03667.x","volume":"35","author":"M Zamani","year":"2010","unstructured":"Zamani M et al (2010) Possible association of the CD4 gene polymorphism with vitiligo in an Iranian population. Clin Exp Dermatol 35(5):521\u2013524","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"6855_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/iji.12476","volume":"47","author":"A Bagheri Hamidi","year":"2020","unstructured":"Bagheri Hamidi A et al (2020) Association of MTHFR C677T polymorphism with elevated homocysteine level and disease development in vitiligo. Int J Immunogenet 47(4):342\u2013350","journal-title":"Int J Immunogenet"},{"issue":"5","key":"6855_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1399-0039.1995.tb03127.x","volume":"46","author":"M Bunce","year":"1995","unstructured":"Bunce M et al (1995) Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46(5):355\u2013367","journal-title":"Tissue Antigens"},{"issue":"1","key":"6855_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.humimm.2020.10.007","volume":"82","author":"DMT e Oliveira","year":"2021","unstructured":"e Oliveira DMT et al (2021) pHLA3D: updating the database of predicted three-dimensional structures of HLA with HLA-DR, HLA-DQ HLA-DP molecules. Hum Immunol 82(1):8\u201310","journal-title":"Hum Immunol"},{"issue":"2","key":"6855_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1096-8628(19980305)76:2<183::AID-AJMG12>3.0.CO;2-H","volume":"76","author":"M Zamani","year":"1998","unstructured":"Zamani M, Cassiman JJ (1998) Reevaluation of the importance of polymorphic HLA class II alleles and amino acids in the susceptibility of individuals of different populations to type I diabetes. Am J Med Genet 76(2):183\u2013194","journal-title":"Am J Med Genet"},{"issue":"4","key":"6855_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1365-2133.2003.05539.x","volume":"149","author":"I Le Poole","year":"2003","unstructured":"Le Poole I et al (2003) Expansion of vitiligo lesions is associated with reduced epidermal CDw60 expression and increased expression of HLA-DR in perilesional skin. Br J Dermatol 149(4):739\u2013748","journal-title":"Br J Dermatol"},{"key":"6855_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fimmu.2019.00360","volume":"10","author":"SJ Gaudino","year":"2019","unstructured":"Gaudino SJ, Kumar P (2019) Cross-talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis. Front Immunol 10:360","journal-title":"Front Immunol"},{"issue":"2","key":"6855_CR23","doi-asserted-by":"publisher","first-page":"e1171447","DOI":"10.1080\/2162402X.2016.1171447","volume":"6","author":"B Seliger","year":"2017","unstructured":"Seliger B, Kloor M, Ferrone SJ (2017) HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance. Oncoimmunology 6(2):e1171447","journal-title":"Oncoimmunology"},{"key":"6855_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fimmu.2017.00194","volume":"8","author":"A Takeuchi","year":"2017","unstructured":"Takeuchi A, Saito T (2017) CD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function. Front Immunol 8:194","journal-title":"Front Immunol"},{"issue":"1","key":"6855_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1600-0749.2005.00279.x","volume":"19","author":"PR Fain","year":"2006","unstructured":"Fain PR et al (2006) HLA class II haplotype DRB1* 04\u2013DQB1* 0301 contributes to risk of familial generalized vitiligo and early disease onset. Pigment Cell Res 19(1):51\u201357","journal-title":"Pigment Cell Res"},{"issue":"3","key":"6855_CR26","first-page":"403","volume":"4","author":"KS Deo","year":"2018","unstructured":"Deo KS, Ganjre SA (2018) Genetics of multiplex familial vitiligo as cases and controls: a preliminary report. Int J Res 4(3):403","journal-title":"Int J Res"},{"issue":"4","key":"6855_CR27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.13187\/ejm.2015.10.190","volume":"10","author":"GA Abdullah","year":"2015","unstructured":"Abdullah GA et al (2015) The association between Human Leukocyte Antigen-DRB1 and vitiligo. Eur J Med 10(4):190\u2013194","journal-title":"Eur J Med"},{"issue":"11","key":"6855_CR28","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1182\/blood-2012-12-470872","volume":"122","author":"S Stevanovi\u0107","year":"2013","unstructured":"Stevanovi\u0107 S et al (2013) HLA class II upregulation during viral infection leads to HLA-DP\u2013directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood 122(11):1963\u20131973","journal-title":"Blood"},{"issue":"3","key":"6855_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","volume":"16","author":"A Alkhateeb","year":"2003","unstructured":"Alkhateeb A et al (2003) Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 16(3):208\u2013214","journal-title":"Pigment Cell Res"},{"issue":"157","key":"6855_CR30","first-page":"2","volume":"6","author":"X Kang","year":"2017","unstructured":"Kang X et al (2017) Association of HLA-DRB1* 1201\/02, DRB1* 0701\/02, DQA1* 0302 and DQB1* 0303 Alleles with population Uygur patients of vitiligo. Clon Transgen 6(157):2","journal-title":"Clon Transgen"},{"issue":"1","key":"6855_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1046\/j.1365-2133.2001.04288.x","volume":"145","author":"M Zamani","year":"2001","unstructured":"Zamani M et al (2001) Linkage and association of HLA class II genes with vitiligo in a Dutch population. Br J Dermatol 145(1):90\u201394","journal-title":"Br J Dermatol"},{"issue":"11","key":"6855_CR32","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/art.39780","volume":"68","author":"SF Ling","year":"2016","unstructured":"Ling SF et al (2016) HLA\u2013DRB1 amino acid positions 11\/13, 71, and 74 are associated with inflammation level, disease activity, and the health assessment questionnaire score in patients with inflammatory polyarthritis. Arthritis Rheumatol 68(11):2618\u20132628","journal-title":"Arthritis Rheumatol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06855-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-06855-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06855-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T09:22:22Z","timestamp":1641806542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-06855-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6855"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06855-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-813285\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}